Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations

Dana-Farber Cancer Institute · with Beth Israel Deaconess Medical Center, Boston Medical Center · NCT06716580

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 40–80 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Not applicable
Target enrollment
1000
US sites recruiting
1
Study start
April 1, 2025
Record last updated
July 15, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening.

The name of the test used in this research study is:

-Circulating free DNA (cfDNA) Assay

Being studied: Circulating Tumor DNA (ctDNA) Assay

Conditions: Lung Cancer; EGFR Gene Mutation

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria (Aims 1, 2, and 3) for Group 1 (50 through 80 years of age):

  • Non-tobacco using (currently)
  • Self-identify as East Asian (including Southeast Asian) or Hispanic/Latinx.
  • East Asian includes those who self-identify as Chinese, Japanese, Korean, Taiwanese, Malaysian
  • Southeast Asian includes those who self-identify as Cambodian, Thai, Vietnamese, Filipino
  • Latinx includes those who self-identify as a person of Central or South American and the Caribbean including, Cuban, Puerto Rican, and Dominican culture or origin, excluding individuals originating from Spain
  • Aims 1 and 2: Able to complete and understand the study's informed consent in English, Mandarin, Cantonese, Japanese, Korean, Vietnamese, Spanish, Portuguese, or Cape Verdean
  • Aim 3: Able to complete and understand the study's informed consent and participate in a focus group in English, Mandarin, Vietnamese, or Spanish.

Inclusion Criteria (Aims 1, 2, and 3) for Group 2 (40 through 49 years of age):

  • Non-tobacco using (currently)
  • Self-identify as East Asian (including Southeast Asian) or Latinx, if any of the following criteria are met:
  • Family history of EGFR positive LC L858R or exon 19
  • Personal history of remote cancer that is not LC or other thoracic malignancies, including thymoma, thymic carcinoma, or sarcoma, as long as it was resolved over 5 years ago
  • History of TB, asthma requiring daily inhaled corticosteroids or chronic bronchitis
  • Symptoms of lung cancer for the past month, including hemoptysis, unexplained weight loss, voice hoarseness, cough or worsening cough, dyspnea or worsening dyspnea
  • Excluding individuals who concurrently present with fever, covid/influenza/RSV/adenovirus infection, runny nose, sore throat, productive cough with green or yellow sputum
  • Aims 1 and 2: Able to complete and understand the study's informed consent in English, Mandarin, Cantonese, Japanese, Korean, Vietnamese, Spanish, Portuguese, or Cape Verdean
  • Aim 3: Able to complete and understand the study's informed consent and participate in a focus group in English, Mandarin, Vietnamese, or Spanish.

Exclusion Criteria (Aims 1, 2, and 3) for Groups 1 and 2:

  • Having had a chest CT scan in the last 3 years or having an anticipated chest CT scan during the enrollment period.
  • Having a current cancer or history of cancer within the last 5 years, excluding localized non-melanoma skin cancer and breast ductal carcinoma in situ.
  • More than 400 lifetime cigarettes (i.e., 20 packs) of smoking or tobacco use
  • Adults unable to provide informed consent
  • Individuals \<40 years of age
  • Prisoners
  • Pregnant women
  • Personal diagnosis of lung cancer
  • Not able to be compliant with study requirements

Recruiting US locations

  • Dana-Farber Cancer Institute

    Boston, MA 02215

    Site contact: Narjust Florez, MD · 617-582-7335 · narjust_florez@dfci.harvard.edu

Study contacts (from the official record)

  • Fernando Pacheco · 857-215-2794 · fernando_pacheco@dfci.harvard.edu
  • Kylee Coonradt · 617-582-8846 · kylee_coonradt@dfci.harvard.edu
All healthy volunteers studies in Massachusetts →
EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening… (NCT06716580) | Bored Studies